DUBLIN – Funding for European biopharmaceutical companies is down 43 percent for the first three quarters of 2016 compared with the same period last year, with total equity investment dropping to $2.335 million from $4.119 million.
DUBLIN – Shares in Summit Therapeutics plc surged as much as 128 percent during trading on Nasdaq Tuesday on news of a deal with Sarepta Therapeutics Inc., which is in-licensing European rights to its pipeline of utrophin modulators in development for Duchenne muscular dystrophy (DMD).
DUBLIN – Carrick Therapeutics Ltd. raised an eye-catching $95 million in a series A funding and declared its ambition to become Europe's leading oncology company by pursuing a new approach to cancer therapy.
DUBLIN – Shares in Medigene AG rose nearly 17 percent Thursday on news of an alliance with Bluebird Bio Inc. to develop T-cell receptor-based immunotherapies, in which it is getting $15 million up front plus more than $1 billion in potential milestone payments covering preclinical and clinical development, regulatory approval and product sales.
DUBLIN – 4SC AG has spun out its immunology arm into a new startup, Immunic AG, which has raised €17.5 million (US$19.6 million) in a series A round to take forward two programs in autoimmune disease.
DUBLIN – Shareholders in Viratherapeutics GmbH could be in line for a big payday as the company has entered a development and option agreement with Boehringer Ingelheim GmbH worth up to €210 million (US$235 million).
DUBLIN – Shares in GW Pharmaceuticals plc shot up 17.2 percent percent Monday on news that Epidiolex, its liquid formulation of cannabidiol, reached the primary endpoint of a second phase III trial in treatment-resistant Lennox-Gastaut syndrome (LGS), a severe form of childhood epilepsy.
DUBLIN – Even if much of the focus of the inaugural Biopharma Ambition meeting here was, as the name suggests, on how Ireland can compete to win more investment from the global biopharma industry, scheduling Sir Andrew Dillon, CEO of England's National Institute for Health and Care Excellence (NICE), as the final speaker in the final plenary session, suggested a certain amount of realism on the part of the conference organizers.
DUBLIN – A mere four months after its formation, German startup Iomx Therapeutics GmbH raised €40 million (US$44.6 million) in a series A round to develop antibody-based therapeutics against tumor-derived immune checkpoint targets.
DUBLIN – GE Healthcare Life Sciences' $150 million investment in the creation of GE Biopark Cork, which it unveiled this week, is its first foray into building a prefabricated, off-the-shelf biomanufacturing facility that will cater to multiple tenants.
